Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases

Brain metastases occur in up to 25–55% of patients with metastatic HER2-positive breast cancer. Standard treatment has high rates of recurrence or progression, limiting survival and quality of life in most patients. Temozolomide (TMZ) is known to penetrate the blood–brain barrier and is US FDA appro...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Future Oncol
Päätekijät: Zimmer, Alexandra S, Steinberg, Seth M, Smart, Dee Dee, Gilbert, Mark R, Armstrong, Terri S, Burton, Eric, Houston, Nicole, Biassou, Nadia, Gril, Brunilde, Brastianos, Priscilla K, Carter, Scott, Lyden, David, Lipkowitz, Stanley, Steeg, Patricia S
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Future Medicine Ltd 2020
Aiheet:
Clinical Trial Protocol
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7270957/
https://ncbi.nlm.nih.gov/pubmed/32270710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2020-0094
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia